News

Phase III data for eye drug
Enlarge image

Clinical TrialsBelgium

Phase III data for eye drug

17.08.2012 - Belgian biopharmaceutical company ThromboGenics N.V. published encouraging data from two Phase III studies with its eye treatment experimental drug Ocriplasmin.

The studies published in New England Journal of Medicine (NEJM) including in total 652 patients found that the recombinant protein significantly resolved vitreomacular traction and closed macular holes compared to placebo in patients with vitreomacular adhesion (VMA). A health care practitioner, who treated patients in one of the studies said ocriplasmin could help a significant number of patients at an earlier point in their disease and improve their vision much more than surgery, which is the current standard of care.

"Results from the phase III programme with ocriplasmin are significant as they demonstrate the potential for using an enzymatic approach to resolve vitreomacular adhesion. This represents a real advance for patients living with vitreomacular adhesion who currently only have the option of surgery at a later stage of the disease," said Peter Stalmans, Department of Ophthalmology, University Hospitals, Leuven, Belgium. "The majority of patients who achieved resolution of their vitreomacular adhesion after a single intravitreal injection of ocriplasmin showed this positive outcome within the first seven days."

Ocriplasmin is a recombinant, truncated form of human plasmin that works by dissolving the proteins that link the vitreous to the macula. If approved, the drug, couldbecome the first pharmaceutical treatment for vitreomacular adhesion (VMA). Currently vitrectomy, or surgical removal of the vitreous from the eyeball, is the only available treatment for VMA. In patients with VMA, the vitreous adheres in an abnormally strong way to the retina, which can lead to traction on the retina, causing symptoms including impaired vision. Further unresolved traction may lead to the development of macular holes and central blindness.Thrombogenics developed the biologic and plans to market ocriplasmin on its own in the US. In a deal worth up to €300m in milestone payments and royalties Swiss drug maker Novartis’ subsidiary Alcon paid €75m up front in March to license the ex-US rights to the drug, which is currently under review by FDA and EMA.

http://www.european-biotechnology-news.com/news/news/2012-03/phase-iii-data-for-eye-drug.html

EbolaEUFrance

30.09.2014 In the face of the Ebola outbreak sweeping the West African countries, the EMA has started to review investigational treatments for the deadly virus disease.

FinancingSwitzerlandGermanyNetherlandsFrance

26.09.2014 Biotechnology has made the news in the stock market this month, as a wave of companies announced plans to launch IPOs on European exchanges later this year.

ResearchGermany

25.09.2014 After being hit hard by the Andromeda trial data falsification scandal, German biotech Evotec is moving back into calmer waters with new MS research projects.

FinancingNetherlands

23.09.2014 Dutch Biotech VC firm Aglaia has launched a new US$65m fund targeted towards biotechnology startups working on groundbreaking technologies aimed at preventing and curing cancer.

BusinessGermany

19.09.2014 In order to concentrate on the life science business, German industry giant Bayer is splitting off its plastics subgroup as a separate company.

FinanceSwitzerland

18.09.2014 Swiss biopharma Cardiorentis has received a €45m investment from overseas investment firm Healthcare Royalty Partners in order to finance the registration for its heart drug.

PoliticsEU

15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.

BiosimilarsGermanyFrance

12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.

FinancingNetherlands

11.09.2014 Cystic fibrosis specialist Proqr Therapeutics has set the terms for its upcoming IPO at US-American stock exchange NASDAQ.

Clinical TrialsUKSweden

09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CO.DON3.13 EUR5.03%
  • 4SC1.06 EUR3.92%
  • SANTHERA88.65 CHF2.78%

FLOP

  • CYTOS0.19 CHF-9.52%
  • WILEX2.13 EUR-6.99%
  • FORMYCON8.03 EUR-5.42%

TOP

  • PAION3.18 EUR33.6%
  • CO.DON3.13 EUR27.8%
  • FORMYCON8.03 EUR14.2%

FLOP

  • CYTOS0.19 CHF-26.9%
  • ADDEX3.13 CHF-18.1%
  • EVOTEC3.06 EUR-16.8%

TOP

  • SANTHERA88.65 CHF2155.7%
  • PAION3.18 EUR224.5%
  • CO.DON3.13 EUR222.7%

FLOP

  • CYTOS0.19 CHF-95.2%
  • 4SC1.06 EUR-43.9%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 30.09.2014